PatentJul 1, 2026, 10:01 AM
MindWalk Files Patent for AI Drug Discovery Data Architecture
AI Summary
MindWalk Holdings Corp. announced the filing of European patent application No. EP26187897.9, which is directed to high-dimensional data structures for biological subsequences and property inference. This patent aims to protect the enriched biological representation architecture that underpins the company's HYFT® Technology, ReefIQ™ biological context layer, and LensAI™ reasoning workflows. The company believes this model-agnostic data layer provides a durable advantage in life sciences by enabling AI models to retrieve, compare, and reason over biology with traceable context, supporting the growing AI drug discovery market.
Key Highlights
- MindWalk filed European patent application No. EP26187897.9 for high-dimensional biological data structures.
- The patent protects the enriched biological representation architecture for AI drug discovery.
- It underpins MindWalk's HYFT® Technology, ReefIQ™ biological context layer, and LensAI™ reasoning workflows.
- The architecture provides domain-specific context, structured interfaces, and validation for AI agents.
- It builds on the foundational HYFT patent (EP3881326A1) by organizing biological meaning around patterns.
- The approach is model-agnostic, supporting various AI models and workflows.
- The AI in drug discovery market is projected to grow from $5 billion in 2026 to over $8 billion by 2030.
- MindWalk has demonstrated the approach in preclinical dengue and influenza programs.
Price Impact
More from HYFT